IND Readiness & Clinical Strategy - CMC Solutions
We provide the CMC framework necessary for sustainable business and regulatory approval. We support the development of IND/IMPD CMC sections to prevent clinical holds and avoid delays that typically cost programs 12–18 months.
Regulatory Strategy
We support IND CMC section strategy, helping clients navigate evolving frameworks for nucleic acid and protein therapeutics.
CMC Section Strategy
Defining the appropriate level of process description and control strategy for Phase 1, balancing regulatory completeness with the protection of manufacturing know-how.
Analytical Package Development
Establishing reference standards and determining which methods must be validated versus qualified for early-stage submissions.
Phase-Appropriate Development
Calibrating CMC programs to the specific stage of development, from defining the minimum viable CMC package for Phase 1 to preparing for Phase 3 process validation.
Let us help maximize your impact.
Smart molecule design is critical for execution!
Our strategy is built for robustness, success and speed. The correct design strategy saves time and decreases wet lab experiment design space, enables faster synthesis and scale up optimization to accelerate development freeing up your resources. Reduction of royalty and licensing costs and avoid common pitfalls. Reduced COGs and longer-term strategy baked in to ensure compliance with regulatory requirements.
Frequently Asked Questions
How does your CMC support impact project timelines?
By providing a robust framework and developing strong IND/IMPD CMC sections, we help prevent clinical holds and avoid regulatory delays that typically cost biotech programs 12 to 18 months.
What modalities does your regulatory strategy cover?
We provide strategic support to help clients navigate the rapidly evolving regulatory frameworks specifically for nucleic acid and protein therapeutics.
How do you handle the disclosure of proprietary information in early-phase submissions?
For Phase 1 CMC section strategy, we carefully define the appropriate level of process description and control strategy to balance regulatory completeness with the protection of your manufacturing know-how.
How do you approach analytical methods for early-stage submissions?
Our analytical package development focuses on establishing reference standards and determining exactly which analytical methods must be formally validated versus those that only need to be qualified for early-phase regulatory filings.
Is your CMC development strategy adaptable to different clinical stages?
Yes, we practice phase-appropriate development, calibrating our CMC programs to your specific stage—ranging from defining the minimum viable CMC package for Phase 1 all the way to preparing for Phase 3 process validation.